I wrote on June 26 about LLY having a possible blockbuster drug for obesity and about its strong technicals. Since then, LLY has resisted market weakness and hit another ATH today. I continue to hold a small position in this stock and am monitoring it closely for signs that the big funds are buying, in anticipation of continuing good results from their clinical trial. Bad results would likely decimate the stock.
A nice daily RWB pattern.
And a strong monthly chart with multiple GLBs.
.